Reversible Cerebral Vasoconstriction Syndrome
7
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Florida Cerebrovascular Disease Biorepository and Genomics Center
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
Triggers And Risk Factors to Develop a Reversible Cerebral Vasoconstriction Syndrome
Endothelial Dysfunction in Reversible Cerebral Vasoconstriction Syndrome
RCVS: The Rational Approach to Diagnosis and Treatment
Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus
Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome